| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues |
| Two Product Concentration Risk | 30.1 | 25.4 | 17.1 | | | | | |
| Pharmaceutical Compounding | | 72.5 | 48.9 | 51.2 | | | | |
| |
| EBIT |
| Pharmaceutical Compounding | | 25.7 | 11.0 | 8.9 | | | | |
| Pharmaceutical Drug Development | | -8.7 | -0.2 | -0.5 | | | | |
| Corporate | | -13.7 | -8.2 | 8.2 | | | | |
| |
| Mix |
| Two Product Concentration Risk | 34.0% | 35.0% | 35.0% | | | | | |
| Pharmaceutical Compounding | | 100.0% | 100.0% | 100.0% | | | | |
| |
| Growth |
| Two Product Concentration Risk | 18.7% | 48.3% | | | | | | |
| Pharmaceutical Compounding | | 48.3% | -4.5% | | | | | |